Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-06-17

FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)

View source ↗

Summary

FDA approved a supplemental application for SUBLOCADE (buprenorphine) by Indivior Inc., updating/expanding its labeling for the treatment of opioid use disorder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUBLOCADE (buprenorphine extended-release)

Snippet

SUPPL AP for SUBLOCADE (BUPRENORPHINE)